Scoping review update on somatic symptom disorder that includes additional Chinese data

Somatic symptom disorder(SSD)is a new diagnosis introduced into the Diagnostic and Statistical Manual of Mental Disorders,Fifth Edition(DSM-5),which is expected to solve the diagnostic difficulties of patients with medically unexplained symptoms.Based on the previous work,this review aims to comprehensively synthesise updated evidence related to SSD from recent years in English publications and,more extensively,from data published in Chinese language journals.The scoping review update was based on an earlier scoping review and included Chinese language publication data from China National Knowledge Internet(CNKI),WANFANG and WEIPU between January 2013 and May 2022 and data from PubMed,PsyclNFO,and Cochrane Library between June 2020 and May 2022.Initially,2984 articles were identified,of which 63 full texts were included for analysis.In China,SSD is mainly applied in scientific research,but it also shows good predictive validity and clinical application potential.The mean frequency of SSD was 4.5%in the general population,25.2%in the primary care population and 33.5%in diverse specialised care settings.Biological factors,such as brain region changes and heart rate variability,are associated with the onset of sSD.Psychological impairment related to somatic symptoms is the best predictor of prognosis.While adolescent SSD is significantly associated with family function,SSD overall is associated with an increased dysfunction of cognition and emotion,decreased quality of life,and high comorbidity with anxiety and depressive disorders.Further research is needed on suicide risk and cultural and gender-related issues.Updating the data of Chinese language studies,our research enriches the evidence-based findings related to the topics addressed in the text sections of the SSD chapter of DSM-5.However,research gaps remain about SSD reliability,population-based prevalence,suicide risk,and cultural and gender-related issues.